Novo Nordisk: The Pill That Could Close The Gap With Lilly (NYSE:NVO)
· seekingalpha.com
Novo Nordisk A/S stays a Buy as oral Wegovy surges and the GLP-1 pipeline strengthens; an attractive 2028 P/E suggests upside. Click to read more on NVO.
I’m a lifelong entrepreneur who, alongside my other ventures, has always made time for the markets. Driven by genuine passion, I’ve been active with varying...